Research

ISCI Research

Basic Cell Biology, Blood, Bone & Skin, Cancer, Cardiovascular, Diabetes and Nervous System.

Clinical Trials

Clinical Trials

Phase I/II clinical trials testing mesenchymal stem cells (MSC) in cardiology and wound care.

Leadership

ISCI Leadership

Renowned physician-scientists set a vision for the future of regenerative medicine.

Latest News

Stem Cell Studies Build Momentum toward Therapy for Age-Associated Frailty

Buoyed by promising results of a Phase I study demonstrating the safety of mesenchymal stem cell therapy to treat frailty in older adults, researchers at the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School of Medicine have taken it a step further. Now Phase II randomized, placebo-controlled trial findings have verified their initial study.

Read more on the Miller School Web site »

Study Shows Stem Cell Therapy Dosing Matters in Ischemic Cardiomyopathy

The Phase II TRIDENT study, led by Joshua M. Hare, M.D., and colleagues at the University of Miami Miller School of Medicine, found that a dose of 100 million allogeneic human mesenchymal stem cells, versus 20 million, was more effective in decreasing scar tissue and restoring left ventricular ejection fraction in study of 30 people with ischemic cardiomyopathy.

Read more on the Miller School Web site »

New Ethics Guidelines for Gene Editing

On August 3, The American Journal of Human Genetics published the American Society for Human Genetics’ policy statement on germline gene editing in humans. Representing the Miller School on the task force was Rosario Isasi, J.D., M.P.H., a bioethicist and lawyer whose work focuses on the regulation of human genetic technologies. We asked Isasi to discuss the policy statement and its broad implications.

Read more on the Miller School Web site »